Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 51 to 75 of 373

TitleTypeExpected publication date
Fruquintinib for previously treated metastatic colorectal cancer ID6274Technology appraisal guidance
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Technology appraisal guidance
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]Technology appraisal guidance
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]Technology appraisal guidance
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]Technology appraisal guidance
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia [ID4042]Technology appraisal guidance
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]Technology appraisal guidance
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]Technology appraisal guidance
Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast mediaNICE guideline
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]Technology appraisal guidance
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]Technology appraisal guidance
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]Technology appraisal guidance
Pegzilarginase for treating arginase-1 deficiency [ID4029]Highly specialised technology
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]Technology appraisal guidance
Maternal and child nutritionNICE guideline
Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implantsInterventional procedures guidance
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]Technology appraisal guidance
Urinary Tract Infection (recurrent): antimicrobial prescribingNICE guideline
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]Technology appraisal guidance
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Technology appraisal guidance
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]Technology appraisal guidance
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B after first-line chemotherapy [ID3887]Technology appraisal guidance
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]Technology appraisal guidance
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All